PatientsVille.com Logo

Staphylococcal and Cipro

PatientsVille

Staphylococcal Symptoms and Causes

Staph is short for Staphylococcus, a type of bacteria. There are over 30 types, but Staphylococcus aureus causes most staph infections (pronounced "staff infections"), including

  • Skin infections
  • Pneumonia
  • Food poisoning
  • Toxic shock syndrome
  • Blood poisoning (bacteremia)

Skin infections are the most common. They can look like pimples or boils. They may be red, swollen and painful, and sometimes have pus or other drainage. They can turn into impetigo, which turns into a crust on the skin, or cellulitis, a swollen, red area of skin that feels hot.

Anyone can get a staph skin infection. You are more likely to get one if you have a cut or scratch, or have contact with a person or surface that has staph bacteria. The best way to prevent staph is to keep hands and wounds clean. Most staph skin infections are easily treated with antibiotics or by draining the infection. Some staph bacteria such as MRSA (methicillin-resistant Staphylococcus aureus) are resistant to certain antibiotics, making infections harder to treat.

Check out the latest treatments for staphylococcal

staphylococcal treatment research studies

Cipro clinical trials, surveys and public health registries


Find Drug Side Effect reports



Cipro Side Effects

Arthralgia (909)
Pain In Extremity (638)
Tendonitis (458)
Diarrhoea (434)
Pain (402)
Dizziness (389)
Pyrexia (382)
Tendon Pain (379)
Nausea (379)
Anxiety (375)
Headache (367)
Myalgia (362)
Paraesthesia (360)
Rash (358)
Gait Disturbance (357)
Insomnia (354)
Tendon Rupture (351)
Renal Failure Acute (346)
Fatigue (318)
Asthenia (308)
Dyspnoea (270)
Confusional State (267)
Hypoaesthesia (264)
Pruritus (255)
Vomiting (229)
Muscular Weakness (212)
Oedema Peripheral (202)
Erythema (200)
Tendon Disorder (197)
Back Pain (196)
Muscle Spasms (194)
Abdominal Pain (187)
Depression (186)
Burning Sensation (183)
Neuropathy Peripheral (179)
Feeling Abnormal (174)
Joint Swelling (170)
Malaise (166)
Urticaria (160)
Musculoskeletal Pain (158)
Chest Pain (145)
Convulsion (144)
Tinnitus (141)
Abasia (140)
International Normalised Ratio Increased (139)
Abdominal Pain Upper (127)
Hypersensitivity (125)
Blood Creatinine Increased (125)
Condition Aggravated (125)
Palpitations (123)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Staphylococcal Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  A Comparative Study Between Two Formulations of the Ciprofloxacin Hydrochloride + Hydrocortisone Otic Suspension
Condition: Otitis Externa
Interventions: Drug: Cipro HC;   Drug: Ciprofloxacin HCl and Hydrocortisone
Outcome Measures: Cure (reduced pain, swelling and otorrhea);   Identification of possible side effects
2 Recruiting Ciprofloxacin for Prevention of BK Infection
Condition: BK Virus Infection
Interventions: Drug: Ciprofloxacin;   Drug: placebo
Outcome Measures: BK infection at 6 months post-transplant;   Incidence of urinary tract infections as defined by a midstream urine sample containing 10^4 or more colony-forming units per mL;   Incidence of bacteremic infections at 6 months. Incidence of bacteremia as defined by a single positive blood culture that was not thought to be contaminated.;   Incidence of quinolone-resistant bacterial infections;   Incidence of clostridium difficile infection;   Serious adverse events;   Time to BK infection;   Proportion of patients developing BK infection at 1 year;   First and peak plasma viral loads;   Incidence of acute rejection at 1 year;   Incidence and severity of BK nephropathy, as defined by positive staining of histopathological specimen, at 1 year
3 Recruiting Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Condition: Bronchiectasis
Interventions: Drug: Ciprofloxacin: administered for 28 days on / 28 days off;   Drug: Placebo: administered for 28 days on / 28 days off;   Drug: Ciprofloxacin: administered for 14 days on / 14 days off;   Drug: Placebo: administered for 14 days on / 14 days off
Outcome Measures: Time to first exacerbation;   Mean number of exacerbations per patient per 48 weeks;   Pathogens present at baseline and eradicated at 48 weeks;   Quality of Life: Changes of Saint George's Respiratory;   New pathogens at 48 weeks, not present at baseline;   Changes of Forced Expiratory Volume in 1 second from baseline;   Number of participants with Adverse events as a measure of
4 Recruiting Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes
Condition: Otitis Media in Patients With Tympanostomy Tubes.
Interventions: Drug: Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension;   Drug: CiproDEX® (Ciprofloxacin 0.3%/dexamethasone 0.1%);   Drug: Placebo Sterile Otic Suspension
Outcome Measures: Clinical Success;   Cessation of Otorrhea
5 Recruiting Norfloxacin Versus Ciprofloxacin for Spontaneous Bacterial Peritonitis (SBP) Prevention
Condition: Adverse Reaction to Other Drugs and Medicines
Interventions: Drug: Norfloxacin;   Drug: Ciprofloxacin
Outcome Measures: The prevention rate of spontaneous bacterial peritonitis (SBP);   1 year mortality;   Incidence of infectious event other than SBP;   Hepatorenal syndrome;   Hepatic encephalopathy;   Adverse event of drugs
6 Unknown  TINN Pharmacokinetics (PK) Study Treat Infections iN Neonates
Condition: Pharmacokinetics of Ciprofloxacin in Neonates
Intervention: Procedure: Collection of biological samples
Outcome Measures: Ciprofloxacin plasma concentration and population pharmacokinetic (PK) parameters;   PK variables;   Tolerability;   Safety;   Clinical/microbiological outcomes
7 Recruiting Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)
Condition: Bronchiectasis
Interventions: Drug: Ciprofloxacin DPI (BAYQ3939);   Drug: Placebo
Outcome Measures: Time to first exacerbation;   Mean number of exacerbations per patient per 48 weeks;   Pathogens present at baseline and eradicated at 48 weeks;   Changes of Saint George's Respiratory Questionnaire score from baseline to 48 weeks;   New pathogens at 48 weeks, not present at baseline;   Changes of Forced expiratory volume in 1 second from baseline to 48 weeks;   Number of participants with Adverse events as a measure of safety and tolerability
8 Recruiting A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Humans
Condition: Plague
Interventions: Drug: Ciprofloxacin;   Drug: doxyxcycline
Outcome Measures: all cause mortality;   time to defervesence;   antimicrobial associated adverse events
9 Not yet recruiting Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects
Conditions: Healthy Volunteers;   Non-smokers
Interventions: Drug: Pracinostat;   Drug: Itraconazole;   Drug: Ciprofloxacin
Outcome Measures: Peak plasma concentration Cmax in healthy nonsmoking subjects given a single-dose of pracinostat;   Number of participants with Adverse Events as a measure of safety and tolerability of single-dose pracinostat when administered with itraconazole or with Ciprofloxacin in healthy nonsmoking adult subjects.;   Peak plasma PK concentration Area Under the Curve (AUC)AUC 0-t, AUC 0-inf in healthy nonsmoking subjects given a single dose of pracinostat
10 Recruiting Population Pharmacokinetics of Anti-infectious Drugs in Children
Conditions: Pediatrics;   Ceftazidime;   Ciprofloxacin;   Voriconazole
Interventions: Drug: Ceftazidime;   Drug: Ciprofloxacin;   Drug: Voriconazole
Outcome Measures: Population pharmacokinetic parameters and factors explaining variability;   Covariability factors explaining the variability (age, biological data, pharmacokinetics factors, associated treatments...)
11 Recruiting A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa
Condition: Otitis Externa
Interventions: Drug: Ciprofloxacin/Dexamethasone;   Drug: Ciprodex (R);   Drug: Placebo
Outcome Measures: Clinical Success;   Resolution of Symptoms
12 Recruiting Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy
Condition: Urinary Tract Infections
Interventions: Drug: Fosfomycin 3 g;   Drug: Ciprofloxacin 500 mg
Outcome Measures: Bacteriuria;   Urinary Tract Infection;   Sepsis;   Pathogens present in urine and antimicrobial resistance;   Bacteremia;   Hematuria;   Hemospermia;   Rectal bleeding;   Urinary retention;   Difficulty for miction;   Genitourinary infections associated to fever (>38ºC);   Number of participants with adverse events
13 Recruiting BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent
Conditions: HIV;   Salivary Gland Disease;   Benign Lymphoepithelial Lesion
Interventions: Drug: Ciprofloxacin;   Drug: Placebo
Outcome Measures: (BK) Virus replication and shedding;   Salivary function
14 Recruiting Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
Conditions: Urinary Tract Infections;   Acute Pyelonephritis
Interventions: Drug: Finafloxacin 800 mg i.v. once daily;   Drug: Finafloxacin placebo i.v. once daily;   Drug: Finafloxacin 800 mg tablets (as four 200 mg tablets) once daily;   Drug: Finafloxacin placebo tablets (as four tablets) once daily;   Drug: Ciprofloxacin 400 mg i.v. two times daily;   Drug: Ciprofloxacin placebo i.v. two times daily;   Drug: Ciprofloxacin 500 mg oral (as two 250 mg capsules) two times daily;   Drug: Ciprofloxacin placebo oral (as two capsules each) two times daily
Outcome Measures: Clinical and microbiological response of patients with cUTI or pyelonephritis.;   The clinical and microbiological response at the On Therapy (OT) visit (Day 3).;   The clinical and microbiological response at the End of Therapy (EoT) visit (Day 10).;   The clinical and microbiological response at the End of Study (EoS) visit (Day 24).;   The safety and tolerability of multiple doses of finafloxacin of both 5 days and 10 days of treatment with finafloxacin (i.v. and oral) in subjects with cUTI, compared to 10 days of Ciprofloxacin (i.v. and oral).;   The predictive capacity of PK/PD data of both 5 days and 10 days of treatment with finafloxacin (i.v. and oral) in subjects with cUTI, using 10 days of Ciprofloxacin (i.v. and oral) as reference on clinical outcomes (EMA guidance).
15 Recruiting Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Condition: Infection
Interventions: Drug: Ciprofloxacin;   Drug: trimethoprim-sulfamethoxazole;   Drug: cefuroxime;   Drug: ceftriaxone;   Drug: gentamicin;   Drug: amikacin;   Drug: aztreonam;   Drug: imipenem
Outcome Measures: Infection rates;   Infection rate;   Demographics and medical co-morbidities;   Genus and species of rectal swab isolates with their antibiotic susceptibility profiles
16 Recruiting Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis
Condition: Non Cystic Fibrosis Bronchiectasis
Intervention: Drug: Ciprofloxacin
Outcome Measures: Time to first exacerbation;   Number of exacerbations
17 Recruiting A Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics/Pharmacodynamics of BAYQ3939 in Patients With Bacterial Pneumonia
Condition: Pneumonia
Intervention: Drug: Ciprofloxacin (Cipro, BAYQ3939)
Outcome Measures: Safety variables will be summarized using descriptive statistics based on adverse events collection;   AUC (Area under the blood concentration/time curve);   Cmax (Maximum observed concentration);   AUC/MIC (Minimum inhibitory concentration);   Cmax/MIC;   AUC/MPC (Mutant prevention concentration);   Cmax/MPC;   Clinical response rate based on resolution of signs and symptoms;   Microbiological response rate, assessed as eradication rate based on microbiologically evaluable patients;   Test of cure rate based on resolution of signs, symptoms, and the clinical response
18 Recruiting Antibiotics and Hydroxychloroquine in Crohn's
Condition: Crohn's Disease
Interventions: Drug: Ciprofloxacin;   Drug: Doxycycline;   Drug: Hydroxychloroquine;   Drug: Budesonide
Outcome Measures: • Remission, defined as Crohn's Disease activity index (CDAI) <150 at 10 weeks without addition of any other medication or treatment for the Crohn's Disease.;   • Remission, defined as CDAI ≤150 maintained through to 24 weeks;   • Remission, defined as CDAI ≤150 maintained through to 52 weeks;   • Remission defined as CDAI <150 at 4 weeks;   • Response defined as a fall in CDAI by >70 points at 4 weeks and 10 weeks;   • Markers of cost (days admitted to hospital, days unable to carry out normal daily activities, need for surgery);   • Quality of life at 4 weeks, at 10 weeks, or Early Withdrawal;   • Patient global assessment of symptom severity by 10 cm visual analogue score at 4 weeks, at 10 weeks, or Early Withdrawal;   • Adverse Events and possible drug-related side effects: nausea, diarrhoea, mood disturbance, sleep disturbance - will all be assessed at each visit;   • Fall in Faecal Calprotectin
19 Recruiting A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration
Condition: Pancreatic Cysts
Interventions: Drug: Ciprofloxacin;   Other: Placebo (for Ciprofloxacin)
Outcome Measures: Number of patients with pancreas cyst infection after EUS-guided pancreatic cyst aspiration;   Secondary outcomes;   secondary outcome
20 Unknown  Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases
Condition: Febrile Neutropenia
Interventions: Drug: Ciprofloxacin;   Drug: cefepime
Outcome Measures: Treatment efficacy;   Toxicity